FDA approves Crinetics' once-daily oral acromegaly treatment

Crinetics Pharmaceuticals (CRNX) has secured FDA approval for PALSONIFY (paltusotine), the first once-daily oral treatment for acromegaly, representing a significant shift from traditional injectable therapies. This approval, based on strong Phase 3 trial data demonstrating biochemical control and symptom reduction, positions the company for substantial commercial growth with an anticipated early October launch. Despite a recent EPS miss, Crinetics maintains a robust financial position and positive analyst sentiment, underscoring the commercial potential of PALSONIFY and its broader pipeline.

Analysis

Crinetics Pharmaceuticals (CRNX) has achieved a pivotal milestone with the FDA approval of PALSONIFY (paltusotine), the first once-daily oral treatment for acromegaly. This approval marks a significant paradigm shift from the traditional standard of care involving injectable medications and is supported by robust data from two Phase 3 trials, PATHFNDR-1 and PATHFNDR-2, which demonstrated both biochemical control and symptom reduction. Financially, the company appears well-capitalized for the commercial launch, slated for early October, evidenced by a strong balance sheet with more cash than debt and a current ratio of 17.8. While the most recent Q2 2025 earnings showed an EPS miss at -1.23 versus a -1.1 forecast, this was offset by a revenue beat of $1 million against a $750,110 estimate. Analyst sentiment remains broadly positive, with Overweight and Buy ratings, although minor downward price target adjustments from Citizens JMP (to $86) and Stifel (to $58) suggest a recalibration of expectations. The company's long-term growth prospects are further supported by a Marketing Authorization Application for paltusotine under review in the EU and additional pipeline developments, including a Phase 3 trial for carcinoid syndrome and an Orphan Drug Designation for atumelnant.

Key Decisions for Investors

• The FDA approval is a major de-risking event, shifting the primary focus from clinical trial risk to commercial execution risk; investors should now model revenue scenarios based on the upcoming October launch of PALSONIFY.
• Monitor early prescription and sales data following the launch, as the initial ramp-up will be a critical indicator of market adoption and the key driver for near-term stock performance.
• While the approval is a significant positive, note the recent EPS miss and minor analyst price target reductions, suggesting that close attention should be paid to launch-related operating expenses and cash burn rate in coming quarters.
• Evaluate the company not just on the acromegaly launch but also on its pipeline progress, including the EU regulatory timeline for paltusotine and clinical advancements for carcinoid syndrome and atumelnant, which represent future value catalysts.